Back to today’s briefing

Story perspectives

Cleveland Clinic tests CRISPR nanodrug CTX310 in 15 volunteers

9/9/2026

6 1 Full Breakdown

Summary

Story summary

Cleveland Clinic researchers tested the gene-editing nanodrug CTX310 in 15 volunteers.
CTX310 uses a CRISPR system to edit the ANGPTL3 gene in liver cells.
Trials in the United States and China suggest a single injection may control LDL-C for years.
People with natural ANGPTL3 mutations have very low cholesterol and rarely develop heart disease.

1 of 1

Story summary

Cleveland Clinic researchers tested the gene-editing nanodrug CTX310 in 15 volunteers.
CTX310 uses a CRISPR system to edit the ANGPTL3 gene in liver cells.
Trials in the United States and China suggest a single injection may control LDL-C for years.
People with natural ANGPTL3 mutations have very low cholesterol and rarely develop heart disease.